Roman S.
- Country
- Slovakia
- Department
- Private practice Urology
Research Overview
- Phase III Study of Lutetium (177Lu) Vipivotide Tetraxetan in PSMA-Positive Oligometastatic Prostate Cancer in Adult Males
- Efficacy and Safety of Capivasertib Plus Abiraterone in PTEN-Deficient Metastatic Hormone-Sensitive Prostate Cancer: A Phase III Randomized, Double-Blind, Placebo-Controlled Trial
- Phase 3 Randomized, Double-Blind Trial of Talazoparib and Enzalutamide Versus Placebo and Enzalutamide in DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer
Data & Insights
Has run more than one trial at 127 of 319 partner sites.
Specializations
Advanced Prostate Cancer Treatment
This investigator specializes in the treatment of metastatic castration-resistant prostate cancer (mCRPC), conducting research on novel therapeutic combinations and treatment approaches.
- Hormone Therapy Innovations
- Combination Treatment Strategies
- Novel Therapeutic Agents
Key focus includes evaluating treatment efficacy in patients who have not received prior chemotherapy or novel hormonal therapy.
Precision Oncology
Expertise in targeted therapeutic approaches for specific prostate cancer subtypes, including research on PTEN-deficient tumors and DDR gene mutations.
- Molecular-Based Treatment Selection
- Biomarker-Driven Therapies
- Personalized Medicine Approaches
Specializes in matching specific genetic profiles with targeted therapeutic interventions.
Advanced Imaging and Treatment
Investigates innovative imaging techniques including PSMA-PET scanning for treatment monitoring and the application of radiotherapy combinations in prostate cancer management.
- Molecular Imaging Applications
- Therapeutic Response Assessment
- Oligometastatic Disease Management
Focuses on integrating advanced imaging with therapeutic decision-making.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.